

Immedica UK and Ireland methodological note: ABPI/IPHA Patient organisation disclosure 2024

Introduction

This document summarises the methodology used in preparing Immedica Pharma UK disclosure report on Transfers of Value (ToV) to Patient Organisations, in accordance with the ABPI/IPHA Code of Practice for 2024 activities.

Definitions

Patient Organisation (PO): non-for-profit legal person/entity (including the umbrella organisation to which it belongs), mainly composed of patients and/or caregivers, that represents and/or supports the needs of patients and/or caregivers and which business address, place of incorporation or primary place of operation is in the UK or Ireland.

Reporting Period: Covers a full calendar year.

Time of Disclosure: In line with ABPI/IPHA requirements, disclosures must be made within 6 months after the end of the relevant Reporting Period and the information disclosed must remain in the public domain for a minimum of 3 years after the time such information is first disclosed.

ToVs are handled according to the cash basis principle, hence a specific ToV is as a general rule registered when the payment is made.

Transfer of Value (ToV): Financial support and/or significant indirect/non-financial support provided by Immedica Pharma to a Patient Organisation:

For support:

- the monetary value of financial support and of invoiced costs.
- the non-monetary benefit that the PO receives when the non-financial support cannot be assigned to a meaningful monetary value

For contracted services the total amount paid per PO over the Reporting Period.

A description of the nature of the support or services provided that is sufficiently complete to enable the average reader to form an understanding of the nature of the support or the arrangement without the necessity to divulge confidential information.

Publication

All interactions with patient organisations are made public on the Immedica global website as well as submitting a link to the ABPI disclosure platform.